Our results provide novel mechanisms for understanding the methylation in the GBM and identify some biomarkers for prognosis of two different GBM types of MGMT promoter unmethylated or methylated GBM; we also reveal the fundamental differences between those groups and emphasize the available treatment strategies for GBM. The gene discussed is MGMT; the disease is glioblastoma.